<DOC>
	<DOCNO>NCT00369954</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) give different way may kill tumor cell . PURPOSE : This phase II trial study side effect well give gemcitabine together carboplatin work treat patient persistent recurrent ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer respond previous cisplatin carboplatin .</brief_summary>
	<brief_title>Gemcitabine Carboplatin Treating Patients With Persistent Recurrent Ovarian Epithelial Cancer , Primary Peritoneal Cancer , Fallopian Tube Cancer That Responded Previous Cisplatin Carboplatin</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival patient persistent recurrent platinum-sensitive ovarian epithelial , fallopian tube , primary peritoneal cancer treat gemcitabine hydrochloride intraperitoneal carboplatin . - Evaluate systemic regional toxicity regimen patient . Secondary - Determine overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive gemcitabine hydrochloride IV 30 minute follow intraperitoneal carboplatin day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 3 year . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer Persistent recurrent disease Nonmeasurable disease Platinumsensitive disease Must attain clinically defined complete response prior platinum ( cisplatin carboplatin ) taxanebased combination chemotherapy regimen Patients partial response disease progression firstline therapy eligible No disease recurrence within 6 month completion firstline platinumtaxane therapy Must undergone laparoscopy laparotomy either following : Secondlook surgery complete response firstline therapy No negative secondlook surgery Secondary cytoreductive surgery recurrent disease ≥ 6 month completion firstline chemotherapy No great 1 cm residual disease completion laparoscopy laparotomy AND diffuse carcinomatosis Disease must confine peritoneal cavity Retroperitoneal disease ≤ 1 cm completion prior surgery allow Not candidate high priority GOG protocol No tumor low malignant potential PATIENT CHARACTERISTICS : GOG performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN SGOT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Neuropathy ( sensory motor ) ≤ grade 1 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection require antibiotic No invasive malignancy within past 5 year except nonmelanoma skin cancer No extensive intraabdominal adhesion PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior surgery chemotherapy No prior intraperitoneal therapy No prior gemcitabine hydrochloride No 1 prior regimen ( include consolidation chemotherapy ) ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer No radiotherapy &gt; 25 % marrowbearing area No prior abdominalpelvic radiotherapy No prior cancer treatment would preclude study therapy No prior therapy direct malignant tumor , include biological agent ( unless part frontline therapy ) , immunologic agent , vaccine , secondline chemotherapy , hormonal therapy Concurrent hormone replacement therapy allow No concurrent amifostine protective reagent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>